University of Utah COVID-19 Hydrochloroquine Trial
Status:
Active, not recruiting
Trial end date:
2021-10-01
Target enrollment:
Participant gender:
Summary
A novel coronavirus, SARS-CoV-2, is responsible for a rapidly spreading pandemic that has
reached 160 countries, infecting over 500,000 individuals and killing more than 24,000
people. SARS-CoV-2 causes an acute and potentially lethal respiratory illness, known as
COVID-19, that is threatening to overwhelm health care systems due to a dramatic surge in
hospitalized and critically ill patients. Patients hospitalized with COVID-19 typically have
been symptomatic for 5-7 days prior to admission, indicating that there is a window during
which an effective intervention could significantly alter the course of illness, lessen
disease spread, and alleviate the stress on hospital resources.
There is no known treatment for COVID-19, though in vitro and one poorly controlled study
have identified a potential antiviral activity for HCQ. The rationale for this clinical trial
is to measure the efficacy and safety of hydroxychloroquine for reducing viral load and
shedding in adult outpatients with confirmed COVID-19.